home / stock / bctxw / bctxw news

BCTXW News and Press, BriaCell Therapeutics Corp. Warrant From 10/03/23

Stock Information
Company Name: BriaCell Therapeutics Corp. Warrant
Stock Symbol: BCTXW
Market: NASDAQ
Website: briacell.com
Menu
BCTXW BCTXW Quote BCTXW Short BCTXW News BCTXW Articles BCTXW Message Board
Get BCTXW Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTXW - BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria...
BCTXW - BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's co...

BCTXW - BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology...

BCTXW - BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
BCTXW - BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders

August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-sta...

BCTXW - BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting

Shareholders overwhelmingly approved the spinout of BriaPro Therapeutics (Spinco) which includes specific pipeline assets including Bria-TILsRx and and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer Share reorganization expected to take place...

BCTXW - BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS(TM) Immunotherapy for Cancer

NCI award (non-dilutive grant) further validates novel personalized off-the-shelf immunotherapy approach; and may facilitate future non-dilutive funding opportunities PHILADELPHIA and VANCOUVER, British Columbia, Aug. 16, 2023 (GLOBE NEWSWIRE) --  BriaCell Therapeutics Corp. (Nasda...
BCTXW - FDA Approves BriaCell's Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives,...

BCTXW - BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

Special Shareholder Meeting to be Held in July 2023 PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotech...

BCTXW - BriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per Share

PHILADELPHIA and VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is ple...
Previous 10 Next 10